Solid Tumors Clinical Trial
Official title:
Phase I Trial of Sequential Azacitidine and Valproic Acid Plus Carboplatin in the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
The goal of this clinical research study is to find out if giving azacitidine with valproic
acid plus carboplatin can help control advanced cancer. The safety of this treatment will be
studied as well. Researchers will also collect some extra blood samples for molecular marker
studies (studies that may help researchers predict how participants respond to the combined
therapy).
There were to be two phases of this study: a Phase 1 portion to find acceptable doses of the
study drug combination, and a Phase 2 portion to study the response rates to the treatment
schedule. The study did not proceed to the Phase 2 portion.
The Study Drugs:
Researchers want to see if the combination of azacitidine, carboplatin, and valproic may
work better together to control advanced cancer.
- Azacitidine is designed to activate ("turn on") certain genes in cancer cells whose job
is to fight tumors, which may also make azacitidine work better with other anti-tumor
drugs.
- Carboplatin is designed to block the growth of cancer cells by stopping cell division,
which may cause the cells to die.
- Valproic acid is an anti-seizure medication that may also have cancer-fighting
abilities. This drug may be able to activate tumor-fighting genes, causing cancer cells
to die.
Phase 1 (Dose Escalation) and Phase 2 (Treatment):
Participants will be enrolled on Phase 1 of the study in groups of 3. Each group will
receive a different combination of the study drugs. If the first group of 3 tolerates the
study drug combination well, the next group of 3 will be enrolled, and their dose(s) of
carboplatin and/or valproic acid will be higher than the last group. Each new group will get
a higher dose of carboplatin and/or valproic acid. If 1 of the 3 participants has a serious
side effect at a certain dose level, 3 more participants may be added at that dose level to
check the safety of the combination. If no more participants at that dose level have serious
side effects, the next dose level will be tested. However, if a second participant has a
serious side effect, then the dose level before that one will be considered the "maximum
tolerated dose" (MTD). Once the MTD is found, participants will be enrolled on Phase 2 of
the study.
Participants enrolled on Phase 2 were to be given the MTD level of the study drug
combination; however, study did not progress to Phase 2.
Participants on both phases were to have the same treatment schedule and study tests
performed. The only difference between Phase 1 and Phase 2 was to be the dose level of the
study drug combination being given.
Study Treatment:
If eligible, participants received the study treatment on a 28-day treatment cycle.
On Day 1 of each cycle, they receive an injection of azacitidine just under the skin or by
vein over 30 minutes once a day for 5 days in a row.
On Day 3 and Day 10 of each cycle, they receive carboplatin by vein over 60 minutes.
On Days 5-11 of each cycle, they take valproic acid by mouth once a day with or without
food.
On Day 12 of each cycle, they may receive an injection of NeulastaTM (pegfilgrastim) just
under the skin, depending on whether the study doctor thinks it is needed to help boost your
white blood cell count.
On Days 13-28 of each cycle, they have a "rest period" from the study drugs before beginning
a new 28-day cycle of treatment.
Study Visits:
At certain time points, they have the following tests/procedure performed during study
visits:
On Day 5 and Day 11 of Cycles 1-3, about 1 tablespoon of blood drawn before treatment for
molecular marker studies. These tests will be performed to look for a link between genetic
characteristics and response to the study drug treatment.
Within the last 72 hours (3 days) of each cycle, blood drawn (about 1 tablespoon) and urine
collected for routine tests. After the start of each cycle, blood drawn (about 1 tablespoon)
once weekly for routine tests.
Within 7 days before starting each new cycle, evaluation to see if you may be experiencing
any side effects.
After the end of every 2 cycles (about every 8 weeks), an x-ray and either a CT scan or an
MRI scan to re-evaluate the cancer.
Length of Study:
Participants will continue to receive treatment on this study, as long as the disease does
not get worse and you do not experience any intolerable side effects.
End-of-Treatment Visit:
Once treatment has ended for any reason, participants will come back for an end-of-treatment
visit to have the following tests/procedures performed:
- You will have a complete physical exam.
- You will have urine collected and blood drawn (about 1 tablespoon) for routine tests.
- You may have a CT scan or an MRI scan to remeasure and re-evaluate the cancer.
Up to 65 patients were eligible to take part in this study. All were to be enrolled at M. D.
Anderson. Study halted after Phase 1 without progressing to second phase.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
| Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
| Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
| Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |